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1. Introduction 
Semliki Forest virus (SFV), a member of the alpha 
virus group, contains four structural proteins. One of 
them, the C-protein (mol. wt. approx. 33 000), is a 
constituent of the nucleocapsid and the other three, 
Er (mol. wt. 49 000) Ez (mol. wt. 52 000) and E3 
(mol. wt. approx. 10 000) are glycoproteins located 
in the virus membrane which surrounds the nucleo- 
capsid [l] . It appears now well established that all 
four structural proteins are formed from a common 
precursor, p-130, by post-translational cleavage [2] . 
The C-protein seems to be located at the N-terminal 
and Er at the C-terminal end of the precursor [3-S] 
(fig.1). The only intermediate of the cleavage process 
which is relatively stable is the p-62 which yields Ez 
and E3 in a process which appears to be coupled to 
the final steps in the assembly of the virion [ 1,6] . 
Some other intermediates can be isolated by using 
amino acid analogues, inhibitors of proteolysis, or 
temperature sensitive mutants [6,7]. The details of 
the cleavage process are not known. 
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Fig.lriA) The gene order of the structural proteins of SFV 
(Data from [ 3-51). (B) A schematic representation of the 
set of released nascent polypeptide-puromycin molecules 
assumed to arise in the experimental conditions used. The 
dotted lines show the primary cleavage sites. 
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In the present communication an experiment is 
described which was designed to answer the question 
whether cleavage can occur at the junctions C-p-62 
and p-62-Er on the nascent polypeptide chain, or 
whether most of the p-l 30 polypeptide must be 
completed prior to processing. Puromycin was used 
to release nascent chains from the polysomes as 
puromycin-peptides [8]. The concentration of puro- 
mycin was kept sufficiently low, to allow synthesis 
of long peptides and even completed chains. The 
appearance of the mature virion proteins under these 
conditions may yield information on the processing 
of the precursor (c.f. fig.1). 
The results suggest hat cleavage can occur between 
C and p-62 soon after the completion of the C-protein 
sequence, while Er must be almost completed before 
cleavage between p-62 and Er takes place. 
2. Materials and methods 
HeLa cells in monolayer cultures and the prototype 
strain of Semliki Forest virus were cultivated as 
described previously [9] . Labelling of virus specific 
polypeptides was performed by incubating the infected 
cells in methionine-free Eagles minimum essential 
medium containing 50 PCi of [35S]methionine (200 
Ci/mmole, Amersham) per 60 mm petri dish. Puro- 
mycin (Nutritional Biochemicals) was added to the 
desired concentrations 15 min prior to the isotope, 
and the same concentration was maintained until the 
cells were harvested. Whole cell extracts were prepared 
. . . . 
as described by Keranen and Kaarramen [6] For the 
determination of total [35S] methionine incorporation 
aliquots were taken into 10% trichloroacetic acid, 
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heated to 90°C for 20 min and the precipitates col- 
lected on nitrocellulose filters and counted. Samples 
for electrophoretic analysis were treated with sodium 
dodecyl sulphate and mercaptoethanol at 90°C for 
3 min and analyzed on 7.5% polyacrylamide gels as 
described [9]. 
3. Results and discussion 
Monolayer cultures of HeLa cells were infected 
with SFV. 5 h after the infection the cells were 
exposed to different concentrations of puromycin. 
After a 15 min incubation period [35S]methionine 
was added, and 15 min later unlabelled methionine 
to a final concentration of 1 mM. After an additional 
5 min incubation period the cells were washed and 
whole cell extracts prepared. As expected, increasing 
concentrations of puromycin resulted in decreasing 
amounts of acid precipitable “S activity in the 
extracts (fig.2). 
The samples obtained with O-20 pg/ml of puro- 
mycin were then analyzed for their content of distinct 
virus-specific polypeptide species. Because E, and E2 
are difficult to resolve from each other on polyacryl- 
amide gels, especially for quantitative purposes, a 
relatively short pulse was used to assure that most of 
the labelled Ez was present in its precursor form p-62 
[6]. The gel electrophoresis pattern of the control 
sample (fig.3A) shows prominent peaks of C, E 
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Fig.2. The inhibition of protein synthesis in SFV infected 
HeLa cells by puromycin. The HeLa cells were exposed to 
[ ssS] methionine in the presence of varying concentrations 
of puromycin as described and the incorporation of 3sS into 
acid insoluble material determined. 
(mostly E,) and p-62 together with some p-97, a 
protein which contains tryptic peptides from El and 
Ez [5]. With increasing concentrations of puromycin 
a relative increase in the ‘background’ activity over 
the entire gel is observed (fig.3). The viral polypep- 
tides and especially the C-protein could, however, be 
detected even if the relative abundance of the viral 
polypeptides was changed considerably. Their ratios 
were calculated from samples in which the background 
was not too high, i.e. up to 5 pg/ml of puromycin. 
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Fig.3. Infected HeLa cells were labelled with [ 35S]methionine 
in the presence of (A) 0 pg/ml; (B) 2 fig/ml; (C) 10 pg/ml 
puromycin. Whole cell extracts were prepared and subjected 
to analysis on polyacrylamide gels. The viral polypeptide 
species are indicated by arrows; E is the position of E, and 
E, which are not separated in these conditions. 
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Fig.4. Samples obtained after labelling with [asS]methionine 
in the presence of different concentrations of puromycin 
were analyzed on polyacrylamide gels. The ratios of p-62/E, 
(X), C/p-62 (0) and C/E, (a) were calculated and are pre- 
sented as the function of the puromycin concentration. 
Fig.4 shows that the ratios of C to El and p-62 were 
greatly increased by puromycin treatment, while the 
El to p-62 ratio varied only slightly. 
The roughly constant p-62 to E, ratio suggests 
that whenever a p-62 molecule was released from the 
precursor the El chain was also almost completed. 
C-protein could apparently be formed without a 
concomitant formation of the other polypeptides, i.e. 
it could be cleaved from the nascent precursor poly- 
peptide before termination. 
The above results were obtained in puromycin 
treated cells so the conditions differ distinctly from 
the normal. Thus the conclusions must be considered 
with care. It should, however, be pointed out that a 
cleavage scheme with ‘nascent’ cleavage between C 
and p-62 and a ‘completed chain’ cleavage between 
p-62 and Er appears reasonable from a biological 
viewpoint. The C-protein is rapidly associated with 
the viral RNA in the formation of the nucleocapsids 
[9] , while the three membrane proteins are inserted 
into cellular membranes and glycosylated in the 
biogenesis of the sites on the host cell plasma mem- 
brane through which the nucleocapsids bud in the 
final maturation step [ 10,l l] . In addition the kinetics 
of C-protein formation after synchronous initiation 
[4] support this scheme, and recent data by Kaluza 
[ 121 suggest hat some glycosylation of a common 
envelope protein precursor must occur prior to 
further processing. 
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